Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas
Public ClinicalTrials.gov record NCT04283669. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Open-label, Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas
Study identification
- NCT ID
- NCT04283669
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Enrollment
- 12 participants
Conditions and interventions
Interventions
- Crizotinib Drug
Drug
Eligibility (public fields only)
- Age range
- 6 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 17, 2020
- Primary completion
- Feb 24, 2025
- Completion
- Feb 24, 2025
- Last update posted
- Mar 12, 2026
2020 – 2025
United States locations
- U.S. sites
- 15
- U.S. states
- 13
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| The University of Alabama at Birmingham (Site 700) | Birmingham | Alabama | 35294 | — |
| Univ of California @ Los Angeles (Site 325) | Los Angeles | California | 90027 | — |
| Children's National Medical Center (Site 775) | Washington D.C. | District of Columbia | 20010 | — |
| Children's HealthCare of Atlanta (Site 950) | Atlanta | Georgia | 30324 | — |
| Lurie Childrens Hospital of Chicago (Site 350) | Chicago | Illinois | 60611 | — |
| University of Chicago (Site 850) | Chicago | Illinois | 60637 | — |
| Indiana University (Site 400) | Indianapolis | Indiana | 46202 | — |
| Johns Hopkins University (Site 250) | Baltimore | Maryland | 21287 | — |
| Children's Hospital Boston (Site 725) | Boston | Massachusetts | 02115 | — |
| Washington University - St. Louis (Site 900) | St Louis | Missouri | 63110 | — |
| New York University Medical Center (Site 200) | New York | New York | 10016 | — |
| Memorial Sloan Kettering Cancer Center (Site 210) | New York | New York | 10065 | — |
| Cincinnati Children's Hospital Medical Center (Site 800) | Cincinnati | Ohio | 45229-3039 | — |
| Children's Hospital of Philadelphia (Site 750) | Philadelphia | Pennsylvania | 19096 | — |
| Childrens Medical Center - Univ. of Texas SW (Site 917) | Dallas | Texas | 75235 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04283669, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 12, 2026 · Synced May 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04283669 live on ClinicalTrials.gov.